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However, rapid advancements in murine modeling and disease phenotyping have demonstrated roles for other T-cell subsets in asthma that can in some cases synergize with T helper (Th)2 responses. These advances have also revealed a broadened role for Th2 T cells in asthma pathogenesis than was first thought. Here, we will review new functions of Th2 T cells and the role of new T-cell subsets in the context of a Th2 disease.
Th2 T-Cell-Mediated Immunity in Asthma
The identification of IL-2, IL-4, and IL-5 enabled the segregation of T cells producing these cytokines into Th1 or Th2 cells. 2 The ability of IL-4 and IL-5 to facilitate B-cell class switching and eosinophil recruitment established a plausible link between T cells expressing these cytokines and allergic ABBREVIATIONS: CD = cluster of differentiation; CXCR5 = CXC chemokine receptor 5; EBI3 = Epstein-Barr virus-induced gene 3; FoxP3 = forkhead box P3; IFN = interferon; ILC2 = type 2 innate lymphoid cell; iTr35 = IL-35-generated regulatory T cell; OVA = ovalbumin; Tfh = follicular B-helper T cell; TGF = transforming growth factor; Th = T helper; Treg = regulatory T cell disease. Many studies have implicated enhanced levels of T cells producing type 2 cytokines (IL-4, IL-5, and IL-13) in asthma; these cells are known to be enriched in the BAL and lung tissue of people with atopic asthma. 3, 4 Moreover, strategies attempting to deplete Th2 T cells through the reduction of GATA3 expression, a required Th2 transcription factor, 5 through the use of a
DNAzyme that targets and cleaves GATA3 messenger RNA, has been demonstrated to ameliorate airway inflammation in murine models of allergic airway disease, 6 and, in a randomized, double-blind, placebocontrolled trial, to attenuate allergen-induced early and late-phase asthmatic responses in subjects with allergies. 7 These, and many other studies, established the belief that asthma was primarily the result of a Th2-mediated immune response. Further confirming this belief was the establishment of numerous murine models wherein the selective ablation or blockade of one or more of these cytokines led to complete resolution of disease. [8] [9] [10] [11] Since these findings, numerous antibodies have been developed, with the goal of treating allergic disease by selectively depleting IL-4, IL-5, and IL-13. Some notable successes have been made with anti-Th2 cytokine antibodies, 12, 13 supporting the importance of Th2 cytokines in allergic asthma. Importantly, success of these trials has been dependent on identifying a target patient population, through disease phenotyping, that is amenable to therapy; specifically, this entails identifying subjects with asthma with a predominantly Th2 asthmatic phenotype, through the use of high eosinophils or periostin as enrollment or patient stratification criteria. 14 In trials with less stringent patient stratification, anticytokine strategies have led to little improvement in disease. Although it is plausible that there have been confounding factors associated with potentiation of cytokine activity by treatment with anticytokine antibodies, 15 it is also possible that these strategies were less efficacious than predicted because of the heterogeneity of clinical asthma. Careful clinical phenotyping of patient populations, by cluster analysis, has led to the establishment of numerous asthma endotypes, or known subtypes of disease, with distinct pathologic mechanisms. 16, 17 These studies, in the context of failed anti-Th2 cytokine strategies have firmly established that asthma can no longer be considered a disease constrained to exaggerated Th2 responses, but rather, a heterogeneous syndrome that culminates in airflow obstruction through a variety of mechanisms. Amphiregulin is an epidermal growth factor that acts to restore epithelial integrity following acute injury by inducing the proliferation and differentiation of epithelial cells and keratinocytes. [44] [45] [46] ILC2s also produce amphiregulin following activation, which can mediate epithelial integrity in the absence of T cells. 47 Finally, IL-33 can also induce the recruitment and differentiation of alternatively activated macrophages, an innate cell that can contribute to the resolution of inflammation and restoration of tissue homeostasis. 48, 49 Thus, as our focus moves beyond inflammation, evidence indicating the importance of lymphocytes interacting with the epithelium and innate immune cells continues to mount.
T-Cell Plasticity and Asthma Heterogeneity
As mentioned, allergic asthma has long been thought to be primarily driven by Th2 responses. However, evidence indicates that Th1 and Th2 responses may coexist in asthma. A study examining the Th1 and Th2 cytokine-producing capabilities of peripheral blood mononuclear cells and BAL cells from subjects with asthma and control subjects who had atopic or nonatopic conditions revealed that T cells obtained from subjects with asthma produced significantly more interferon (IFN)-g on stimulation, with no differences in IL-4 production noted. 50 This observation led to the suggestion that there may be a superimposition of Th1 responses onto allergen-specific Th2 responses in asthma. Similarly, in a study of 34 subjects with steroidresistant asthma, 14 subjects were nearly devoid of eosinophils, but the remaining subjects had expectedly high levels of eosinophils and mast cells. 51 In this report, it was suggested that perhaps the asthmatic disease in the patients without eosinophils had begun as typical Th2-driven eosinophilic disease and progressed to the observed eosinophil-deficient phenotype. In accordance with these findings, the transfer of Th1-polarized T cells into mice with preexisting Th2 allergic lung disease did not inhibit disease but rather enhanced airway dysfunction. 52 In a study comparing mild to moderate asthma against severe asthma, analysis of BAL fluid revealed that subjects with severe asthma possessed fourfold more IFN-g-positive T cells, significantly enhanced IFN-g levels in the BAL, and enhanced secretion of IFN-g by ex vivo cultured T cells. 53 Intriguingly, this study identified low levels of secretory leukocyte protease inhibitor, a serine proteinase inhibitor involved in wound healing, 54 produced by airway epithelial cells, in addition to high levels of IFN-g, to be a marker of severe asthma in both humans and mice.
The dose of the allergen may affect the asthmatic phenotype. A murine model of allergy to fungi has supported this claim, as repeated low-dose exposure of mice to fungi yielded eosinophilic lung inflammation, but high-dose challenge led to neutrophilic and Th1-dominated lung inflammation. 55 Studies such as these have led to the hypothesis that asthma is a fluid immune disorder wherein Th2-and Th1/17-mediated mechanisms represent polar extremes of disease, with patient phenotypes developing and fluctuating between these poles as a result of environmental pollutants and allergen exposure doses.
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Th17 IL-17-producing cells are capable of inducing marked inflammation, predominantly neutrophilic, and mediating the progression of both autoimmune disease and allergic asthma. 57 The possibility of a blended Th2/Th17 cell also has arisen. In 2010, cluster of differentiation (CD)4 þ Th2 T cells that produced IL-17
were found in the peripheral blood mononuclear cells of people with allergic asthma. 58 Elsewhere, a study of 52 subjects with asthma and 25 control subjects found that the number of dual positive Th2/Th17 cells in the BAL correlated with reduced airway function and increased blood eosinophilia. 59 These, and murine, studies suggest
Th2 cells may acquire a Th2/Th17 phenotype. Exposure of people with asthma to environmental pollutants that enhance IL-6 may facilitate differentiation from Th2 to Th2/17. 60 The ability of Th2 T cells to acquire Th17-like function and synergize with Th1 cells in the lungs of people with asthma demonstrates how Th2 T-cell plasticity could facilitate diverging disease mechanisms.
Th9
In 1993, IL-9-expressing CD4 þ T cells were identified, forming the basis for the Th9 subset. 61 Although the precise role of these cells in lung pathogenesis is unknown, murine models have demonstrated that IL-9 can mediate airway inflammation and remodeling (reviewed elsewhere 62 ) . In a murine model of allergic airway inflammation, blockade of IL-9, using a monoclonal anti-IL-9 antibody, protected mice from airway remodeling and airway dysfunction. 63 In contrast, IL-9 blockade, in humans, has been an ineffective treatment of allergic asthma, failing to enhance pulmonary function or reduce medication use or asthma exacerbation rates, in populations with mild 64 and moderate to severe asthma. 65 Taken together, it appears as though IL-9 can propagate allergic inflammation, but the inability of IL-9 blockade to reduce symptoms indicates that it may not do so independently. These findings align with early research wherein IL-9 was found to potentiate Th2 inflammation but be insufficient to drive inflammation independently. 66, 67 In 2013, the ability of IL-9 to augment Th2 responses was revisited. During infection with N brasiliensis, IL-9 receptor-deficient mice were found to have impaired ILC2 accumulation and survival that led to deficient Th2 cytokine production and impaired lung repair. 68 Further examination revealed that IL-9 led to the upregulation of BCL-3 in lung-derived ILC2s, an antiapoptotic protein required for ILC2 survival. Thus, through interaction with ILC2s, IL-9 contributes to the persistence and magnitude of Th2 inflammation. 
Follicular B-Helper T Cells
A population of T cells expressing CXC chemokine receptor 5 (CXCR5) was identified that could home to B-cell follicles and proficiently help B cells produce high-affinity antibodies. These cells were termed "follicular B-helper T cells" (Tfhs). 78 Tfhs are potent inducers of immunoglobulin class switching and antibody production by B cells. Furthermore, the prototypical Tfh cytokine, IL-21, and surface markers (CD40L, inducible costimulator, and so forth) support the survival, activation, and differentiation of B cells. Current evidence suggests that Tfh can differentiate as a distinct T-cell lineage, evolving directly from naïve T cells in the presence of IL-21, 79 or acquire Tfh functionality after previous commitment to Th1 80, 81 or Th2. 82 To date, Tfh function has predominantly been linked to autoimmune diseases such as systemic lupus erythematosus and Sjögren syndrome, 83 with little information about their role in allergic disease. The difficulties identifying a role for Tfhs in allergic asthma may arise from their apparent ability to impair IgE production through secretion of IL-21. 84 However, a study of mild and severe asthma found that the frequency of circulating Tfhs was significantly greater in those with severe asthma and correlated positively with IgE titers. 85 Similarly, in a study of individuals with allergic rhinitis, circulating Tfh populations were notably skewed toward a Th2-like Tfh. 86 ) and migrate to the lung in response to subsequent house dust mite challenges. 89 Thus, it is possible that the plasticity of Tfh enables the development of Th2 responses. Indirect evidence for a role of Tfh in asthma comes from studies of allergen immunotherapy in which effective therapy was linked to reductions in circulating Tfh.
Tregs
The demonstration that the adoptive transfer of CD4 , cytokine-secreting (IL-10 or transforming growth factor [TGF]-b) inducible Tregs. Problematically, the inability to rigorously differentiate inducible Tregs from natural Tregs has limited the ability to identify their relative contributions to the maintenance of peripheral tolerance and progression of allergic asthma. Several putative markers have been used to delineate these cell populations, such as Helios 91 and neuropilin-1.
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However, evidence has suggested that neither is a specific marker of natural Tregs. An elegant adoptive transfer study by Gottschalk et al 94 
